Savara Reports FDA Delay for Molgramostim BLA Review
Yardley, Pennsylvania, United States, November 20, 2026 Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Yardley, Pennsylvania, United States, November 20, 2026 Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has...
SUNRISE, Fla., May 11, 2026 Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...
